| Literature DB >> 20976093 |
J D Holmes1, M E Jenkins, A M Johnson, S G Adams, S J Spaulding.
Abstract
Although dual-task interference has previously been demonstrated to have a significant effect on postural control among individuals with Parkinson's disease, the impact of speech complexity on postural control has not been demonstrated using quantitative biomechanical measures. The postural stability of twelve participants with idiopathic Parkinson's disease and twelve healthy age-matched controls was evaluated under three conditions: (1) without a secondary task, (2) performing a rote repetition task and (3) generating a monologue. Results suggested a significant effect of cognitive load on biomechanical parameters of postural stability. Although both groups increased their postural excursion, individuals with Parkinson's disease demonstrated significantly reduced excursion as compared with that of healthy age-matched controls. This suggests that participants with Parkinson's disease may be overconstraining their postural adjustments in order to focus attention on the cognitive tasks without losing their balance. Ironically, this overconstraint may place the participant at greater risk for a fall.Entities:
Year: 2010 PMID: 20976093 PMCID: PMC2957284 DOI: 10.4061/2010/696492
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Clinical features of individuals with Parkinson's disease.
| Subject | Gender | Age (y) | Duration of Illness (y) | Hoehn & Yahr | UPDRS III | Medication | Dosage total/day |
|---|---|---|---|---|---|---|---|
| PD1 | Female | 67 | 2 | 1.5 | 19 | None | — |
| PD2 | Male | 78 | 8 | 2.5 | 36 | Levodopa/Carbidopa | 650 mg |
| Pramipexole | 2.25 mg | ||||||
| PD3 | Male | 69 | 3 | 2.0 | 23 | Levodopa/Carbidopa | 350 mg |
| PD4 | Male | 58 | 4 | 2.5 | 24 | Pramipexole | 1.5 mg |
| PD5 | Female | 50 | 9 | 2.5 | 20 | Levodopa/Carbidopa | 400 mg |
| Ropinirole | 9.5 mg | ||||||
| PD6 | Male | 60 | 2 | 1.5 | 17 | Pramipexole | 1.5 mg |
| PD7 | Female | 76 | 3 | 2.5 | 26 | Levodopa/Carbidopa CR | 400 mg |
| PD8 | Male | 59 | 5 | 2.0 | 26 | Levodopa/Carbidopa | 300 mg |
| Pramipexole | 3.0 mg | ||||||
| PD9 | Male | 49 | 4 | 2.0 | 28 | Ropinirole | 12.0 mg |
| PD10 | Female | 67 | 8 | 2.0 | 21 | Levodopa/Carbidopa CR | 200 mg |
| Levodopa/Carbidopa | 200 mg | ||||||
| PD11 | Male | 67 | 6 | 2.5 | 21 | Levodopa/Carbidopa | 1000 mg |
| Pramipexole | 2.0 mg | ||||||
| PD12 | Male | 68 | 5 | 2.0 | 28 | Levodopa/Carbidopa | 400 mg |
| Pramipexole | 0.75 mg | ||||||
| Entacapone | 800 mg | ||||||
| Mean | 64.00 | 4.92 | 2.13 | 24.08 | — | — | |
| (SD) | (9.08) | (2.39) | (0.38) | (5.16) |
Figure 1Schematic representation of postural variables.
Means (and standard deviations) for each postural variable, separated by group.
| Healthy older adults | |||
|---|---|---|---|
| COPL (m) | BOSml (%) | BOSap (%) | |
| No task | 0.79 (0.11) | 3.71 (1.32) | 8.74 (2.55) |
| Numerical recitation | 0.94 (0.15) | 4.23 (1.52) | 9.31 (3.11) |
| Monologue | 1.26 (0.23) | 7.35 (4.19) | 14.0 (6.52) |
|
| |||
| Parkinson's disease | |||
|
| |||
| COPL (m) | BOSml (%) | BOSap (%) | |
|
| |||
| No task | 0.65 (0.11) | 4.11 (2.57) | 8.16 (2.07) |
| Numerical recitation | 0.76 (0.16) | 5.21 (3.87) | 9.54 (3.36) |
| Monologue | 0.82 (0.16) | 5.11 (3.03) | 10.20 (3.85) |
Where COPL = length of centre of pressure path; BOSml = medial-lateral centre of pressure excursion range; BOSap = anterior-posterior centre of pressure excursion range.
Figure 2Graphical representation of group by task interaction, across all postural variables; *indicates significantly different from no speech task and numerical recitation see also Table 2.